Article Details

Ventyx revises TYK2 drug plans after lackluster study data | BioPharma Dive

Retrieved on: 2023-11-07 17:07:47

Tags for this article:

Click the tags to see associated articles and topics

Ventyx revises TYK2 drug plans after lackluster study data | BioPharma Dive. View article details on hiswai:

Excerpt

Results showed Ventyx's drug met its goal in a Phase 2 psoriasis trial. But the “magnitude of efficacy” was less than targeted, ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up